Immunotech Biopharm (HKSE:06978) Other Long Term Assets : HK$5.76 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Other Long Term Assets?

Immunotech Biopharm's other long-term assets for the quarter that ended in Dec. 2024 was HK$5.76 Mil.

Immunotech Biopharm's quarterly other long-term assets declined from Dec. 2023 (HK$98.17 Mil) to Jun. 2024 (HK$46.54 Mil) but then stayed the same from Jun. 2024 (HK$46.54 Mil) to Dec. 2024 (HK$5.76 Mil).

Immunotech Biopharm's annual other long-term assets declined from Dec. 2022 (HK$213.95 Mil) to Dec. 2023 (HK$98.17 Mil) and declined from Dec. 2023 (HK$98.17 Mil) to Dec. 2024 (HK$5.76 Mil).

Immunotech Biopharm Other Long Term Assets Historical Data

The historical data trend for Immunotech Biopharm's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm Other Long Term Assets Chart

Immunotech Biopharm Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long Term Assets

Get a 7-Day Free Trial

195.17

299.57

213.95

98.17

5.76

Immunotech Biopharm Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Long Term Assets	Get a 7-Day Free Trial								213.95	189.35	98.17	46.54	5.76

Immunotech Biopharm Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Immunotech Biopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176

Website

https://www.eaal.net

Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.

Executives

Jung Hyun Chul
Evodevo Ltd
Yan Kaijing	2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Cao Longxiang	2201 Interest of corporation controlled by you
Cao Fei	2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si	2501 Other
Yan Xijun	2501 Other
Wu Naifeng	2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited	2501 Other
Li Yunhui	2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
China Resources Company Limited	2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines